Search research articles
Contact Us
Filters
Showing results (791-800 of 1,095) with videos related to
Page
of 110
Sort By:
BJU International
|
June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
Ugo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.
Plos One
|
September 13, 2017
Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study
María Buti, María L Manzano, Rosa M Morillas, et al.
International Journal of Legal Medicine
|
August 15, 2014
Genetic and forensic implications in epilepsy and cardiac arrhythmias: a case series
Sara Partemi, Monica Coll Vidal, Pasquale Striano, et al.
Antimicrobial Agents and Chemotherapy
|
July 25, 2018
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection
Andrea L Cathcart, Henry Lik-Yuen Chan, Neeru Bhardwaj, et al.
Scientific Reports
|
December 18, 2021
Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review
Camila A Picchio, Sabela Lens, Manuel Hernandez-Guerra, et al.
Urologic Oncology
|
June 3, 2017
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
Roberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
Journal of Hepatology
|
July 6, 2026
Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohort
George V Papatheodoridis, George Dalekos, Ramazan Idilman, et al.
Tumori
|
November 30, 2022
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
Giuseppe Procopio, Mélanie Claps, Chiara Pircher, et al.
Alimentary Pharmacology & Therapeutics
|
November 25, 2022
Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg-positive chronic hepatitis B
Josef Wagner, Lilly Yuen, Margaret Littlejohn, et al.
International Journal of Molecular Sciences
|
January 21, 2023
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
Page
of 110
Search research articles
Search
Showing results (791-800 of 1,095) with videos related to
Sort By:
Page
of 110
BJU International
|
June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
Ugo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.
Plos One
|
September 13, 2017
Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study
María Buti, María L Manzano, Rosa M Morillas, et al.
International Journal of Legal Medicine
|
August 15, 2014
Genetic and forensic implications in epilepsy and cardiac arrhythmias: a case series
Sara Partemi, Monica Coll Vidal, Pasquale Striano, et al.
Antimicrobial Agents and Chemotherapy
|
July 25, 2018
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection
Andrea L Cathcart, Henry Lik-Yuen Chan, Neeru Bhardwaj, et al.
Scientific Reports
|
December 18, 2021
Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review
Camila A Picchio, Sabela Lens, Manuel Hernandez-Guerra, et al.
Urologic Oncology
|
June 3, 2017
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
Roberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
Journal of Hepatology
|
July 6, 2026
Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohort
George V Papatheodoridis, George Dalekos, Ramazan Idilman, et al.
Tumori
|
November 30, 2022
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
Giuseppe Procopio, Mélanie Claps, Chiara Pircher, et al.
Alimentary Pharmacology & Therapeutics
|
November 25, 2022
Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg-positive chronic hepatitis B
Josef Wagner, Lilly Yuen, Margaret Littlejohn, et al.
International Journal of Molecular Sciences
|
January 21, 2023
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
Page
of 110